iTOL 102
Alternative Names: iTOL-102Latest Information Update: 31 Mar 2025
At a glance
- Originator iTolerance
- Developer iTolerance; Kadimastem
- Class Stem cell therapies
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Type 1 diabetes mellitus
Most Recent Events
- 07 Mar 2025 Pharmacodynamics data from a preclinical trial in Type 1 diabetes mellitus released by iTolerance (iTolerance pipeline, March 2025)
- 25 Feb 2025 Preclinical trials in Type 1 diabetes mellitus in USA (Parenteral) before February 2025
- 25 Feb 2025 Pharmacodynamics data from a preclinical trial in Type 1 diabetes mellitus released by NLS Pharmaceutics